evorpacept
evorpacept: 4 clinical trials tracked.
evorpacept evidence translation
What we can confirm
4 tracked trials
What it means
What to watch
Prepared research question
What is verified about evorpacept, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence0 indications · 2 study sponsors
Related indications
No linked indication is available.
Clinical Trial Registry Records (4)
Protocol ASPEN-09-03: A Single-arm Phase 2 Multicenter Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Participants With Metastatic HER2-Positive Breast Cancer, a Substudy Under Master Protocol ASPEN-09: A Phase 1b/2, Multicenter, Multi Arm Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies
Primary endpoint: Overall Response Rate (ORR) using RECIST v1.1 based on BICR assessment
A Phase II Study (With Safety run-in) of Evorpacept (ALX148) in Combination With Cetuximab and Pembrolizumab in Patients With Refractory Microsatellite Stable Metastatic Colorectal Cancer
Primary endpoint: Objective Response Rate (ORR)
A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer
Primary endpoint: Incidence of dose-limiting toxicities (DLTs; Part 1)
Phase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agents Compared to Isatuximab With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (RRMM) - Master Protocol
Primary endpoint: Part 1 (dose finding, experimental substudies): Determination of recommended dose of novel agents in combination with isatuximab